Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Substance Profile
Esketamine is the S-enantiomer of ketamine, approved by the FDA in 2019 as a nasal spray (Spravato) for treatment-resistant depression. It shows approximately twice the affinity at the NMDA receptor compared to racemic ketamine and is administered in clinical settings under supervision.
NEGATIVE ALLOSTERIC MODULATOR
No subjective effects data available yet.
Neuroimaging insights from Wistar-Kyoto rats under chronic mild stress: morphological and metabolic brain correlates of treatment-resistant depression.
Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports.
[Esketamine alleviates depression-like behaviors in mice with chronic restraint stress by activating glutamatergic neurons in the medial prefrontal cortex].
Comparative Effectiveness of Single-Dose Epidural Esketamine versus Hydromorphone in Thoracic and Upper Abdominal Surgery: A Randomized Trial.
N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine.
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
<p>Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study</p>
Esketamine counters opioid-induced respiratory depression